OVERVIEW ·     TRACK
RECORD
·     BENEFITS ·     FAQs  ·    WHAT'S NEXT ·      HOW WE
PICK STOCKS
·       SUBSCRIBE ·      PENNYSTOCKSTM
NEWSLETTER  

Forbes Directory - Best of the Web
Best of the Web
(Small Caps)
Barron's > read review
As Featured:
*BARRON's
*CNNfn.com
*BusinessWeek Online
*Wired News
*C/NET
*Barron's Electronic
Edition


*Home
*Links
*Sitemap

The only penny stock site recommended in Barron's and by Forbes.

Online since 1996, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX.

To learn what this site is really about, we urge you to visit the Overview and Track Record pages. However, before doing so, take a glance at a few of our all-time winners. Of course, these are the subsequent gains reached once they hit our target prices and we closed the positions, but it is fun to ponder. The first price was the initial recommendation, followed by the subsequent high, and the eventual ultimate percentage gain. No doubt, you will recognize most of these companies.

Netegrity $2.18 to $73.20 3487%
(acquired by IBM)
Inhibitex $2.35 to $24.08 925%
(acquired by BristolMyersSquibb)
Cellstar $1.44 to $13.50 837%
Iomega $3.25 to $13.90 328%
Nanophase $3.75 to $16.75 347%
Immunomedics $1.44 to $29.12 1922%
Total Renal Care $3.12 to $26.95 741%
Voxware $ .90 to $10.31 1046%
Corvas $3.00 to $23.25 675%
Cytogen $2.12 to $17.50 725%
Verilink $3.00 to $14.62 387%
GeneLabs $2.31 to $10.72 364%
70% FOR GAINS!
70% OF OUR CLOSED POSITIONS
ARE FOR GAINS OF 50%
OR GREATER (see TRACK RECORD)
RIGHT NOW!
IN THE CURRENT NEWSLETTER!

Rated a BUY from several analysts, this marketer of stent platforms recently had an advisory firm take a 6.99% stake in its company; trading near its 52-week low at around $2.75.

Rated a STRONG BUY by FIVE ANALYSTS, this pharma is focusing on developing its reusable needle-free injection technology; trading at about $3.75.

Hold on for the wild rides!
See "What's Next"